Conmed Corp valuation and forecast
Explore the models for Conmed Corp, adjust their assumptions and compare your own valuation with the platform's.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: data-quality checks not passed.
Price vs value
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Analyst recommendations
Monthly trend
- Oct 20267
- Sep 20267
- Aug 20267
Counts of recommendations published by analysts covering Conmed Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.
Price history
Loading chart…
Third-party market data · may be delayed
The assumptions
- Free cash flow (TTM, FY2025 Q4)
- $151M
- Less stock-based pay
- $28.3M
- Cash flow we value
- $146M
- Growth, years 1–5 (base)
- %
- Then fading to
- 2.5%
- Discount rate
- 8.5%
- Net cash added
- -$795M
- Diluted shares
- 31M
What would move the value
- Growth 5 points lower
- −32%
- Growth 5 points higher
- +42%
- Free-cash-flow margin 1 point lower
- −10%
- Discount rate 1 point higher
- −19%
Change in our model value when one input moves, all else equal.
CNMD valuation questions
- How does Fundamentalytics value Conmed Corp?
- We use the models that fit Conmed Corp's business and available financial data: cash-flow model (dcf), forward price-to-earnings vs peers. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.
Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Conmed Corp.